目前曲妥珠单抗、ramucirumab是已经被FDA获批用于晚期胃癌的靶向药物.同时仍正在研究的靶点包括EGFR、PI3K蛋白激酶B/哺乳动物雷帕霉素靶点(mTOR)途径、c-MET以及免疫检查点抑制剂.本综述主要讨论晚期胃癌的分子分型和目前已经用于晚期胃癌的靶向药物,同时讨论临床试验阶段的免疫靶向药物.%At present,trastuzumab and ramucirumab has been approved by the FDA for advanced gastric cancer.There are also many other actively investigated targets,including epidermal growth factor receptor,the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway,c-Met and immune checkpoint inhibition.We focuses on molecular classification of advanced gastric cancer,targeted drugs which have used for advanced gastric cancer and the immune targeted drug clinical trials.
展开▼
